
Windtree Therapeutics, Inc. Common Stock
WINT
WINT: Windtree Therapeutics Inc is a development-stage biotechnology company focused on developing KL4 surfactant therapies for respiratory diseases. Its technology platform includes synthetic, peptide-containing surfactant and novel drug-delivery technologies that deliver aerosolized KL4 surfactants without invasive procedures. Its development program utilizing its proprietary technology platform is AEROSURF which is being developed for the treatment of respiratory distress syndrome in premature infants. It operates in the business segment of research and development of products focused on surfactant therapies for respiratory disorders and diseases, and the manufacture and commercial sales of approved products.
moreShow WINT Financials
Recent trades of WINT by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by WINT's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Istaroxime-containing intravenous formulation for the treatment of acute heart failure (ahf) Feb. 21, 2023
-
Patent Title: Istaroxime-containing intravenous formulation for the treatment of acute heart failure (ahf) Dec. 14, 2021
-
Patent Title: Ventilation circuit adaptor and proximal aerosol delivery system Mar. 14, 2017
-
Patent Title: Lyophilization of synthetic liposomal pulmonary surfactant Jan. 31, 2017
-
Patent Title: Ventilation circuit adaptor and proximal aerosol delivery system May. 31, 2016
Federal grants, loans, and purchases
Followers on WINT's company Twitter account
Number of mentions of WINT in WallStreetBets Daily Discussion
Recent insights relating to WINT
Recent picks made for WINT stock on CNBC
ETFs with the largest estimated holdings in WINT
Flights by private jets registered to WINT